Stratos Wealth Partners LTD. reduced its position in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 6.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 11,726 shares of the medical equipment provider’s stock after selling 826 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zimmer Biomet were worth $1,400,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of ZBH. Asset Dedication LLC lifted its position in Zimmer Biomet by 100.0% during the first quarter. Asset Dedication LLC now owns 250 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 125 shares during the last quarter. Key Financial Inc acquired a new stake in Zimmer Biomet during the first quarter worth approximately $27,000. American National Bank lifted its position in Zimmer Biomet by 100.0% during the first quarter. American National Bank now owns 320 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 160 shares during the last quarter. Larson Financial Group LLC lifted its position in Zimmer Biomet by 94.2% during the second quarter. Larson Financial Group LLC now owns 270 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 131 shares during the last quarter. Finally, Ellevest Inc. lifted its position in Zimmer Biomet by 329.5% during the first quarter. Ellevest Inc. now owns 335 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 257 shares during the last quarter. Hedge funds and other institutional investors own 88.02% of the company’s stock.

Several research analysts have recently commented on ZBH shares. SunTrust Banks raised their target price on shares of Zimmer Biomet from $125.00 to $132.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Citigroup raised their target price on shares of Zimmer Biomet from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. BTIG Research lowered their target price on shares of Zimmer Biomet from $170.00 to $130.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Guggenheim cut shares of Zimmer Biomet from a “buy” rating to a “neutral” rating in a report on Tuesday, April 28th. Finally, UBS Group lowered their target price on shares of Zimmer Biomet from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Four research analysts have rated the stock with a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the company’s stock. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $147.65.

Shares of NYSE:ZBH opened at $134.86 on Friday. The company’s 50 day simple moving average is $125.63 and its 200 day simple moving average is $126.30. The stock has a market capitalization of $27.84 billion, a price-to-earnings ratio of 74.51, a price-to-earnings-growth ratio of 5.33 and a beta of 1.31. Zimmer Biomet Holdings Inc has a 1 year low of $74.37 and a 1 year high of $161.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.69 and a quick ratio of 1.03.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Monday, May 11th. The medical equipment provider reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.53 by $0.17. The firm had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.79 billion. Zimmer Biomet had a net margin of 4.84% and a return on equity of 13.29%. The company’s revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.87 earnings per share. As a group, analysts anticipate that Zimmer Biomet Holdings Inc will post 3.82 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Monday, June 29th were paid a dividend of $0.24 per share. The ex-dividend date was Friday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.71%. Zimmer Biomet’s payout ratio is presently 12.20%.

In other Zimmer Biomet news, insider Sang Yi sold 3,000 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $125.38, for a total transaction of $376,140.00. Following the sale, the insider now owns 2,506 shares of the company’s stock, valued at $314,202.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bryan C. Hanson bought 1,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $113.00 per share, for a total transaction of $113,000.00. Following the purchase, the chief executive officer now owns 54,568 shares of the company’s stock, valued at approximately $6,166,184. The disclosure for this purchase can be found here. Insiders own 0.44% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: What is a blue-chip stock?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.